Tak-981-1501- Phase 1/2 Study Of Tak-981 In Combination With Rituximab In Patients With Relapsed/Refractory Cd20-Positive Non-Hodgkin Lymphoma
Posted Date: May 7, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The purpose of this study is to determine the safety, tolerability and to establish the recommended Phase 2 dose (RP2D) of TAK-981 in combination with rituximab in participants with r/r CD20+ Non-Hodgkins lymphoma in Phase 1, and to evaluate the efficacy of TAK-981 in combination with rituximab in select r/r CD20+ NHL indications in Phase 2. The primary outcome for phase 1 is incidence of emergent adverse events, and the primary outcome measured for phase 2 is Overall Response Rate.
Ecog 0-2, Adequate Organ Function Per Protocol, Have At Least 1 Bidimensionally Measurable Lesion, No Central Nervous System Lymphoma; Active Brain Or Leptomeningeal Metastases, No Prior Allogeneic Hematopoietic Stem-Cell Transplantation, No Other Malignancy Within 3 Years, No Active, Uncontrolled Autoimmune Disease Requiring >20 Mg Of Prednisone Or Equivalent, No Chronic Hepatitis B/C, No Significant Medical Diseases Or Conditions, As Assessed By The Investigators And Sponsor That Would Substantially Increase The Risk-Benefit Ratio Of Participating In The Study.
For More Information:
Uc Cancer Center